These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35123677)

  • 21. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
    Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.
    Seidman JD; Zhao P; Yemelyanova A
    Gynecol Oncol; 2011 Mar; 120(3):470-3. PubMed ID: 21159368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired chemotherapy resistance in ovarian cancer.
    Christie EL; Bowtell DDL
    Ann Oncol; 2017 Nov; 28(suppl_8):viii13-viii15. PubMed ID: 29232469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
    Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
    Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of chemotherapeutic resistance in serous ovarian cancer with low-density custom microarray.
    Zhu HL; Zeng HX; Liang XD; Chang XH; Wang JL; Cui H; Wei LH
    Chin Med J (Engl); 2020 Apr; 133(7):871-873. PubMed ID: 32106126
    [No Abstract]   [Full Text] [Related]  

  • 28. Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst.
    Papoutsis D; Rodolakis A; Haidopoulos D; Sotiropoulou M; Antsaklis A
    Eur J Gynaecol Oncol; 2009; 30(1):103-5. PubMed ID: 19317271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-grade ovarian cancer in an adolescent patient.
    Parker LP; Ramirez PT; Broaddus R; Sightler S; Wolf JK
    Gynecol Oncol; 2001 Jan; 80(1):104-6. PubMed ID: 11136580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases.
    Kasherman L; Madariaga A; Rouzbahman M; Murphy K; Shultz D; Stockley T; Oza AM
    Int J Gynecol Cancer; 2021 Jan; 31(1):139-143. PubMed ID: 32998861
    [No Abstract]   [Full Text] [Related]  

  • 31. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer.
    Grabowski JP; Martinez Vila C; Richter R; Taube E; Plett H; Braicu E; Sehouli J
    Int J Gynecol Cancer; 2020 Apr; 30(4):498-503. PubMed ID: 31996397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary surgery in patients with serous low malignant potential ovarian tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Duvillard P; Morice P
    Int J Gynecol Cancer; 2010 Apr; 20(3):346-52. PubMed ID: 20375795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
    Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
    Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
    Schilder RJ; Blessing JA; Shahin MS; Miller DS; Tewari KS; Muller CY; Warshal DP; McMeekin S; Rotmensch J
    Int J Gynecol Cancer; 2010 Oct; 20(7):1137-41. PubMed ID: 21495215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
    Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
    Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy.
    Gilbert L; Ramanakumar AV; Festa MC; Jardon K; Zeng X; Martins C; Shbat L; Alsoud MA; Borod M; Wolfson M; Papaioannou I; Basso O; Sampalis J
    J Comp Eff Res; 2020 Jun; 9(8):537-551. PubMed ID: 32223298
    [No Abstract]   [Full Text] [Related]  

  • 37. MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
    Gershenson DM; Gourley C; Paul J
    J Clin Oncol; 2020 Nov; 38(32):3731-3734. PubMed ID: 32897828
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
    Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
    Combe P; Chauvenet L; Lefrère-Belda MA; Blons H; Rousseau C; Oudard S; Pujade-Lauraine E
    Invest New Drugs; 2015 Dec; 33(6):1267-70. PubMed ID: 26490654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.